Recent founding proved the importance of LILRB3 in the cancer context, leading to the rapid development of anti-LILRB3 antagonist antibodies and chimeric-antigen receptor T-cells (CAR T-cells) to boost the anti-tumoral response [22]. The gene discussed is LILRB3; the disease is cancer.